Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592472 · ClinicalTrials.gov registry record · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
A Phase 3 study of Renal Cell Carcinoma, sponsored by Xynomic Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
- 20
- Study locations
NCT03592472: Recruiting Phase 3 study of Renal Cell Carcinoma, sponsored by Xynomic Pharmaceuticals.
NCT03592472 is a Phase 3 study of Renal Cell Carcinoma that is actively recruiting participants, run by Xynomic Pharmaceuticals. The registered enrollment target is 413 participants, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592472, a Phase 3 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Xynomic Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Primary Outcome
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by blinded Independent Review Committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pazopanib
- DRUG Abexinostat
Study Locations (20)
Other
- Beijing Cancer Hospital - Beijing
- Zhongshan Hospital Affiliated to Fudan University - Shanghai
- Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica - Candiolo
- A.O. Cannizzaro_UOS Oncologia Medica - Catania
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica - Meldola (FC)
- Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale - Milan
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Helen Diller Family Comphrensive Cancer Center - Hemato - San Francisco
Nebraska
- GU Research Network/Urology Cancer Center - Omaha
- Nebraska Cancer Specialists - Omaha
New York
- Northwell Health/Monter Cancer Center - Lake Success
- Mainstreet Physicans Care - Rochester
Arizona
- University Of UA Cancer Center(UACC)/DH-SJHMC - Phoenix
Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
Ohio
- Precision Cancer Research/Dayton Physicians Network - Treatment - Kettering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What NCT03592472 shows while recruiting
NCT03592472 is an interventional study that assigns participants to a tested intervention. The registered 413 participants enrollment target is mid-sized for trials with a published cap, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03592472 names 20 study sites across 12 states, led by Other, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03592472 about?
NCT03592472 is a clinical study titled "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)". This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
What is the current status of trial NCT03592472?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2018-07-17. Estimated completion is 2028-06-30.
What conditions does trial NCT03592472 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT03592472?
The interventions under investigation include: Placebo (OTHER), Pazopanib (DRUG), Abexinostat (DRUG).
Who is sponsoring clinical trial NCT03592472?
This trial is sponsored by Xynomic Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03592472 being conducted?
This trial has 20 study locations across Arizona, California, Kentucky, Louisiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03592472's enrollment target sits among peer trials
413 20th of 121 higher than 102 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI